---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-035762"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2026-08-03T13:35:12+00:00"
generated_at: "2026-08-03T13:36:07.626038+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Lipocine appoints Michael Grissinger to board of directors

## Summary
- Grissinger appointed as independent director effective August 3, 2026.
- Receives initial option grant of 2,000 shares and annual retainer of $55,000.
- Over 20 years at Johnson & Johnson in licensing and corporate development roles.
- Currently serves on boards of Aprea Therapeutics (APRE) and Adicet Bio (ACET).
- Chairman cites his dealmaking experience to advance pipeline and partnerships.

## SEC filing metadata
- accession: 0001493152-26-035762
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2026-08-03T13:35:12+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315226035762/0001493152-26-035762-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315226035762/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-035762
- JSON: https://secwatch.observer/filing/0001493152-26-035762.json
- Plain text: https://secwatch.observer/filing/0001493152-26-035762.txt

## Key facts
- Executive change
  Michael Grissinger was appointed as director at Lipocine Inc..
  - Action: appointed
  - Role: director
  source text: On August 3, 2026, the Board of Directors of the Company expanded the Board of Directors to five members and appointed Michael Grissinger as a director, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1535955/000149315226035762/0001493152-26-035762-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.